Which business models does Merck & Co use?
What strategic moats does Merck & Co have?
Part IThe Story
The $29.5 Billion Molecule
One drug accounts for 46% of everything Merck sells. Not a category. Not a therapeutic area. A single molecule — pembrolizumab, marketed as Keytruda — generated $29.5 billion in worldwide sales in 2024, making it the bestselling pharmaceutical product on the planet for the second consecutive year. To put that in context: Keytruda alone produces more revenue than the entirety of Bristol-Myers Squibb's oncology franchise, more than Moderna's total sales, more than the GDP of Iceland. And yet this number, staggering as it is, encodes Merck's most dangerous strategic problem. Keytruda's core composition-of-matter patent expires in 2028. The subcutaneous formulation — approved by the FDA in September 2025 — extends protection somewhat, but the cliff is visible, approaching at speed, and the market knows it. In the eighteen months between January 2024 and mid-2025, Merck's share price declined roughly 35% from its highs, even as the company posted record revenue. The market was not punishing Merck for what it earned. It was punishing Merck for what it might lose.
This is the central paradox of one of the world's oldest pharmaceutical companies: Merck has constructed, over 130 years, one of the most scientifically productive drug discovery machines in human history — the company that gave the world statins, developed the first measles vaccine, eradicated river blindness in sub-Saharan Africa, and pioneered checkpoint inhibitor immunotherapy. And all of that history, all of that capability, has been funneled into a revenue profile so concentrated that a single patent expiration could hollow out nearly half the enterprise. The story of Merck is, in one reading, the story of scientific genius compounding over decades. In another, it is a case study in the pathology of blockbuster dependence — and the frantic, brilliant, sometimes desperate maneuvers pharmaceutical companies execute when the clock starts ticking.
By the Numbers
Merck in 2024
$64.2BFull-year worldwide sales
$29.5BKeytruda sales (46% of total revenue)
$8.6BGardasil/Gardasil 9 sales
$5.9BAnimal Health segment sales
~74,000Employees worldwide
$7.65Non-GAAP EPS (FY2024)
$419MWinrevair launch-year sales
20Potential blockbuster drugs in pipeline
An Angel in Darmstadt
The pharmaceutical industry's most confusing corporate genealogy begins in 1668, when a German pharmacist named Friedrich Jacob Merck acquired a small apothecary called the Angel Pharmacy in Darmstadt, Germany. For a century and a half, the Merck family operated as provincial chemists. Then Heinrich Emanuel Merck, taking over in 1816, did something that would become the template for the modern pharmaceutical industry: he applied scientific methods to drug production, isolating alkaloids — morphine, codeine, cocaine — in standardized, reproducible forms. Chemistry, not alchemy. By the end of the nineteenth century, the Merck family business had expanded across the Atlantic.
In 1891, Merck established a subsidiary in New York — Merck & Co. — to capitalize on the booming American market. For two decades, the German parent and American subsidiary operated as a single organism. Then came the rupture. When the United States entered World War I in 1917, the Trading with the Enemy Act classified all German-owned assets as enemy property. The U.S. government seized Merck & Co. and auctioned it off. George Merck, an American citizen and grandson of the founder, purchased the confiscated entity and rebuilt it as an independent American corporation. The original German company — Merck KGaA — survived in Darmstadt. The two Mercks have been legally separate ever since, connected by name and origin but divided by war. Under a complex and frequently litigated agreement, the American company uses "Merck" in the United States and Canada and operates as "MSD" (Merck Sharp & Dohme) everywhere else, while the German company uses "Merck" globally except in North America, where it operates as "EMD Serono."
This corporate schizophrenia — the same name, two unrelated companies, geographically partitioned branding — is more than a curiosity. It is a permanent tax on Merck's global identity, a legacy of the violent twentieth century embedded in the company's letterhead.
📜
Key Milestones
Merck's strategic arc across 130+ years
1668
Friedrich Jacob Merck acquires Angel Pharmacy in Darmstadt, Germany.
1891
Merck & Co. established in New York as a U.S. subsidiary of the German parent.
1917
U.S. government seizes Merck & Co. under Trading with the Enemy Act; George Merck repurchases and rebuilds it.
1953
Merck & Co. merges with Sharp & Dohme, creating MSD and expanding into vaccines.
1985
Roy Vagelos becomes CEO; launches golden era of R&D-driven blockbusters.
1987
Merck donates Mectizan (ivermectin) to eradicate river blindness — forever, for free.
2004
Voluntary withdrawal of Vioxx devastates Merck financially and reputationally.
2014
Keytruda (pembrolizumab) receives first FDA approval for advanced melanoma.
2021
Robert M. Davis succeeds Ken Frazier as CEO.
2024
Keytruda reaches $29.5 billion in annual sales; Merck posts $64.2 billion in total revenue.
The Vagelos Doctrine
If you want to understand why Merck's culture operates differently from most large pharmaceutical companies — and why that difference is both its greatest asset and the source of recurring strategic tension — you need to understand P. Roy Vagelos, the biochemist who ran Merck from 1985 to 1994 and whose intellectual fingerprints remain on the institution three decades later.
Vagelos was the son of Greek immigrants who ran a small restaurant in Rahway, New Jersey — the same city where Merck's U.S. headquarters would eventually sit. He trained as a physician at Columbia, then pivoted to biochemistry research at the National Institutes of Health, where he spent over a decade as head of the biochemistry section. He wasn't a dealmaker or a salesman. He was a bench scientist who happened to develop the organizational instincts of a chief executive. When he joined Merck Research Laboratories in 1975, the company was respected but unfocused, producing solid but unremarkable products. Vagelos made a bet that would define the next era: he restructured the entire R&D operation around hypothesis-driven science, recruiting academic researchers, investing heavily in basic biology, and insisting that Merck's competitive advantage would come from understanding disease mechanisms better than anyone else.
The results were extraordinary. Under Vagelos, Merck developed lovastatin (Mevacor), the first commercially available statin, which opened a therapeutic category that would eventually treat hundreds of millions of patients worldwide. Merck introduced enalapril (Vasotec), a blockbuster ACE inhibitor. The company developed the first recombinant hepatitis B vaccine. During Vagelos's tenure, Merck was named Fortune's "Most Admired Company in America" seven consecutive years — a record that stands unchallenged.
But the decision that most clearly reveals Merck's institutional DNA came in 1987, when Vagelos confronted a problem with no commercial solution. Merck scientists had developed ivermectin for veterinary use (it was spectacularly effective against parasites in livestock). Research showed that a human formulation — eventually branded Mectizan — could cure onchocerciasis, or river blindness, a disease that had blinded millions in sub-Saharan Africa and Latin America. The problem: the people who needed the drug could not pay for it, and no government or international body was willing to fund distribution.
— P. Roy Vagelos, former CEO of MerckWe try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear.
Vagelos decided Merck would manufacture and donate Mectizan to anyone who needed it, for as long as necessary. "For as long as necessary" turned out to mean forever — the Mectizan Donation Program, launched in 1987, continues today and has distributed over four billion treatments. It is, by any measure, one of the most consequential corporate philanthropic acts in history. It also established something that would reverberate through Merck's culture for decades: the belief that the company's legitimacy rested not merely on financial performance but on the moral authority of its science. This was not just sentiment. It became a recruitment tool, a retention mechanism, and an internal compass that guided decisions about pipeline investment, pricing, and access in ways that often baffled Wall Street.
The Vagelos doctrine — science first, profits follow — is the closest thing Merck has to a founding creed. It attracts a certain kind of scientist, a certain kind of leader. It also creates a structural vulnerability: when the science produces a single drug so successful that it dominates the portfolio, the creed offers no easy mechanism for diversification. You cannot will the next breakthrough into existence. You can only fund the search.
The Vioxx Reckoning
Every great pharmaceutical company carries a scar. For Merck, it is Vioxx.
Rofecoxib, marketed as Vioxx, was a COX-2 selective anti-inflammatory drug approved by the FDA in 1999 for the treatment of osteoarthritis, acute pain, and menstrual symptoms. It was a genuine blockbuster — peak annual sales approached $2.5 billion. It was also, according to mounting evidence, associated with an elevated risk of heart attacks and strokes. On September 30, 2004, Merck voluntarily withdrew Vioxx from the global market after a clinical trial showed that patients taking the drug for more than eighteen months faced roughly double the risk of cardiovascular events compared to placebo.
The withdrawal was devastating. Merck's market capitalization dropped by approximately $27 billion in a single day. Thousands of lawsuits followed — at one point, the company faced an estimated 50,000 individual claims and dozens of class actions. The legal and settlement costs would eventually total nearly $5 billion. Careers ended. Reputations were shattered. Congressional hearings dissected Merck's internal communications, with critics arguing the company had known about cardiovascular risks far earlier than it acknowledged. Merck disputed this characterization, maintaining that it had acted responsibly given the evolving scientific evidence and that the voluntary withdrawal itself demonstrated good faith.
What Vioxx did to Merck's culture, though, may have mattered more than what it did to the balance sheet. The company had built its identity on scientific integrity and the moral authority of its research. Vioxx threw that identity into crisis. Internal morale suffered. Recruitment of top scientists became harder. The company entered a period of strategic drift — cutting R&D, losing its pipeline edge, watching competitors like Pfizer and Roche surge ahead in oncology and biologics.
The Vioxx era illustrates a dynamic that recurs throughout pharmaceutical history: the company that is most committed to its scientific identity is most vulnerable when that identity is challenged. The fall hit harder precisely because Merck believed its own story. It would take nearly a decade — and a new class of leaders — to rebuild.
The Lawyer Who Rebuilt the Lab
Kenneth C. Frazier was not the obvious choice to lead Merck. He was not a scientist. He was not a salesman. He was a trial lawyer — the son of a janitor, raised in inner-city Philadelphia, one generation removed from sharecroppers in the rural South. Frazier had joined Merck's legal department in 1992 and made his name defending the company during the Vioxx litigation, where he personally tried one of the bellwether cases and won a jury verdict that helped shift the trajectory of the entire litigation portfolio. His courtroom performance was the kind of thing that gets remembered in corporate corridors for decades — precise, empathetic, devastatingly prepared.
When Frazier became CEO in 2011, Merck was a diminished version of itself. Revenue had been essentially flat for years. The pipeline was thin. The company had completed its acquisition of Schering-Plough in 2009 — a $41 billion deal that added scale but also complexity and integration headaches. Frazier's mandate was to rebuild the research engine while stabilizing operations.
— Kenneth C. Frazier, Harvard Business School interview, 2020I'm the son of a man who was born in the rural South and had a third-grade education. He grew up in the shadow of a real institution — not slavery anymore, but Jim Crow. He used to say to me, 'What you do for work is not who you are. Who you are is how you treat people.'
The most consequential decision of Frazier's tenure — arguably the most consequential decision in Merck's modern history — was one that looked unremarkable at the time. In 2011, Merck's scientists were working on a monoclonal antibody called lambrolizumab, a PD-1 checkpoint inhibitor designed to release the immune system's brakes on cancer cells. Checkpoint inhibition was an emerging but unproven therapeutic concept. Bristol-Myers Squibb was ahead in the race, with nivolumab (Opdivo) progressing through clinical trials. Other pharmaceutical companies viewed PD-1 inhibitors with skepticism — the mechanism was theoretically elegant but clinically uncertain. Merck could have deprioritized the program.
Frazier didn't. Under his leadership, Merck accelerated the clinical development of what would become pembrolizumab — Keytruda. The company pursued an aggressive regulatory strategy, securing breakthrough therapy designation from the FDA and pursuing an initial indication in advanced melanoma. On September 4, 2014, the FDA approved Keytruda for the treatment of advanced or unresectable melanoma in patients who had not responded to other drugs. It was the first PD-1 inhibitor to reach the U.S. market — beating Opdivo by months.
The sequence matters. In the checkpoint inhibitor race, being first meant capturing physician mindshare, building clinical data, and establishing commercial infrastructure before the competition. Merck's clinical teams then executed a label-expansion strategy of breathtaking ambition, running hundreds of trials across dozens of tumor types. Keytruda accumulated approvals in non-small cell lung cancer, head and neck cancer, bladder cancer, renal cell carcinoma, Hodgkin lymphoma, gastric cancer, cervical cancer, hepatocellular carcinoma, and many more — eventually securing more than 40 approved indications globally, the broadest label of any oncology drug in history.
Frazier also made a decision about corporate conscience that would define his public profile. In August 2017, following the deadly white supremacist rally in Charlottesville, Virginia, Frazier resigned from President Trump's American Manufacturing Council — the first CEO to do so — issuing a statement against "hatred, bigotry, and group supremacy." It was a gesture that carried real risk for a company whose business depends on government regulatory approvals, Medicare pricing negotiations, and federal research funding. Several other CEOs followed Frazier's lead, and the council eventually disbanded. But Frazier was first, and the act cemented his reputation as the rare Fortune 500 CEO willing to stake corporate capital on moral principle.
When Frazier stepped down as CEO in 2021, handing the role to Robert M. Davis, he left behind a company utterly transformed — and utterly dependent on a single product.
The Concentration Trap
By 2024, Keytruda's dominance of Merck's revenue profile had reached a level that industry analysts described, with varying degrees of alarm, as unprecedented for a major pharmaceutical company. At $29.5 billion in annual sales — growing 18% year over year, or 22% excluding foreign exchange effects — Keytruda represented approximately 46% of Merck's $64.2 billion in total revenue. No other drug in the company's portfolio came close. Gardasil/Gardasil 9, the HPV vaccine franchise that had been Merck's second pillar, generated $8.6 billion — but that number was declining, down 3% from the prior year, with the China market in particular creating acute headaches as elevated inventory levels forced Merck to temporarily pause shipments, potentially through mid-2025.
The financial paradox was stark. Keytruda was growing faster than any other major oncology drug, expanding into earlier lines of therapy, into adjuvant settings, into combinations with Merck's own pipeline assets and those of partners. The molecule was not merely surviving — it was accelerating. Yet the market treated this growth as a countdown, because the composition-of-matter patent expires in 2028. After that date, biosimilar competitors will be free to enter the market. The precise speed and magnitude of revenue erosion is uncertain — biosimilar competition typically plays out more slowly than small-molecule generic competition — but Wall Street consensus models projected significant revenue losses in the years following patent expiration.
This is the fundamental strategic challenge that CEO Rob Davis inherited and that has consumed the company's capital allocation since he took the helm.
Davis came to Merck from Baxter International, where he had served as CFO. He is not a scientist, not a lawyer — he is a finance executive, a capital allocator, a systems thinker. His temperament is less dramatic than Frazier's, his public profile lower, his instincts more operational. In the context of Merck's strategic moment, this background may be precisely what's needed. The question facing Merck is not "Can we do great science?" — that capability is embedded in the institution's DNA. The question is "Can we replace $29.5 billion in revenue before the patent cliff arrives?" That is an allocation problem, a portfolio construction problem, a timing problem. It is, fundamentally, a CFO's problem.
— Robert M. Davis, Merck Q4 2024 Earnings Call, February 2025We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for Keytruda, which continues to benefit more patients with cancer globally, the successful launch of Winrevair and strong performance of our Animal Health business. Our business remains well positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential.
The Subcutaneous Gambit
The first line of defense against the Keytruda cliff is Keytruda itself — or, more precisely, a reformulated version of it. In September 2025, the FDA approved a subcutaneous injection formulation of pembrolizumab combined with berahyaluronidase alfa. The existing intravenous infusion of Keytruda requires patients to sit in a clinical setting for approximately 30 minutes every three to six weeks. The subcutaneous version can be administered in roughly five minutes, dramatically reducing the time burden on patients and the operational cost for healthcare systems.
This is not merely a convenience upgrade. It is a patent strategy. The subcutaneous formulation carries its own intellectual property protections that extend beyond the 2028 composition-of-matter expiration. While the precise years of exclusivity are subject to legal interpretation and potential challenge, the reformulation is designed to give Merck a differentiated product that biosimilar manufacturers cannot replicate simply by copying the original molecule. If Merck can migrate a substantial portion of Keytruda patients to the subcutaneous formulation before 2028 — and if physicians and payers accept the reformulated product as the standard of care — the revenue erosion from biosimilar entry could be significantly less severe than current models project.
It is, in pharmaceutical terms, the oldest trick in the book: lifecycle management, the art of extending a franchise through reformulation, new indications, and combination therapies. But the scale at which Merck must execute this maneuver is without precedent. There has never been a $29.5 billion drug facing a patent cliff, because there has never been a $29.5 billion drug.
Twenty Blockbusters
The second line of defense is the pipeline. On the February 2025 earnings call, Merck's leadership touted a portfolio of 20 potential new blockbuster drugs — defined as products with projected peak annual sales exceeding $1 billion each — that the company estimated could generate over $50 billion in cumulative future revenue. The number was intended to calm investor nerves about the post-Keytruda era.
The most tangible evidence of pipeline productivity in 2024 was Winrevair (sotatercept), a treatment for pulmonary arterial hypertension that Merck acquired through its $11.5 billion purchase of Acceleron Pharma in 2021. Winrevair generated $419 million in sales in its first partial year on the market — a launch trajectory that, if sustained, could place it among the most successful specialty drug launches in industry history. The drug represents a fundamentally new mechanism of action for PAH, and Merck is expanding clinical trials into broader cardiovascular indications.
Beyond Winrevair, Merck's pipeline spans oncology (where the company is exploring next-generation immunotherapies, bispecific antibodies, and antibody-drug conjugates), cardiovascular and metabolic disease, infectious disease, and — in a revealing late entry — the GLP-1 obesity and diabetes space. In December 2024, Merck signed a licensing agreement with Hansoh Pharmaceutical for an investigational oral GLP-1 receptor agonist, designated MK-4082. The deal was reportedly worth up to nearly $2 billion in milestones. The GLP-1 market, dominated by Eli Lilly and Novo Nordisk, represents one of the largest revenue opportunities in pharmaceutical history — potentially exceeding $100 billion annually by the end of the decade. Merck's entry is late, differentiated only by the oral formulation (most GLP-1 drugs are injectable), and far from guaranteed to succeed. But the sheer size of the opportunity makes it a rational bet.
Merck also licensed MK-2010, an investigational anti-PD-1/VEGF bispecific antibody, from LaNova Medicines — a deal that reflects the company's strategy of extending its immuno-oncology franchise beyond the PD-1 monotherapy paradigm. And the company is advancing clesrovimab, a long-acting monoclonal antibody designed to protect infants from RSV disease, with the FDA accepting a Biologics License Application in late 2024.
The portfolio is real. The question is whether it is real enough, fast enough.
The Animal in the Room
One of the most underappreciated assets in Merck's portfolio sits in a division that receives a fraction of the analytical attention devoted to Keytruda: Animal Health. In 2024, Merck's Animal Health segment generated $5.9 billion in revenue, growing 4% year over year (8% excluding foreign exchange). This makes Merck one of the two largest animal health companies in the world, alongside Zoetis — the Pfizer spinoff that has become a Wall Street darling.
Animal Health is a remarkably stable business with different risk characteristics than human pharmaceuticals. Patent cliffs are less severe — veterinary products face less aggressive generic competition, and the customer base (farmers, veterinarians, pet owners) exhibits different purchasing dynamics. The segment covers livestock products (poultry vaccines, cattle parasiticides), companion animal products (flea and tick preventatives, pain management), and aquaculture — a growing category following Merck's recent acquisition of an aquaculture portfolio.
In any other pharmaceutical company, a $5.9 billion animal health business would be a crown jewel. At Merck, it is overshadowed by the human pharmaceutical franchise to such a degree that investors periodically call for its separation or spin-off, arguing that it would be valued more appropriately as a standalone entity. Merck's management has consistently resisted these calls, arguing that the diversification benefit — and the shared R&D capabilities in biologics and manufacturing — justify the integrated structure.
The Animal Health debate is, in miniature, the strategic debate that defines Merck: Is the company better as a focused human pharmaceutical business, concentrating all capital on the next oncology breakthrough? Or is the diversification — the steady cash flow from livestock vaccines and pet medicines — a form of insurance against the inherent volatility of the drug development lottery?
The Gardasil Complication
For years, Gardasil — Merck's quadrivalent and later nonavalent HPV vaccine — was the second pillar of the company's revenue story. The vaccine, which protects against the strains of human papillomavirus responsible for cervical cancer, throat cancer, and other malignancies, was a triumph of both science and public health. Merck essentially created the market, overcoming significant political and cultural resistance (vaccinating adolescents against a sexually transmitted virus was, to put it mildly, controversial) to build a global franchise.
Gardasil and Gardasil 9 generated $8.6 billion in 2024 — a large number by any standard, but one that masked a troubling trajectory. Sales declined 3% year over year. The problem was concentrated in China, which had become the largest market for Gardasil outside the United States. Elevated channel inventory, weakening demand in a post-COVID environment, and emerging domestic competition from Chinese vaccine manufacturers combined to create a slowdown that Merck's management described with careful understatement. The company paused shipments to China and withdrew its earlier $11 billion sales target for the franchise.
The Gardasil situation illustrates a dynamic that recurs across Merck's portfolio: the tension between first-mover advantage and the inevitability of competitive catch-up. Merck was first with HPV vaccination. It built the market. It captured enormous value. But it could not hold the market permanently — not against local competitors with lower manufacturing costs, not against governments seeking to diversify their vaccine supply chains, not against the natural maturation of a vaccination program that, as penetration increases, exhausts its addressable population.
The Institutional Memory of Science
What distinguishes Merck from most large pharmaceutical companies is not any single product or executive but something harder to quantify: an institutional commitment to science-led drug discovery that has persisted across leadership transitions, strategic crises, and market cycles for nearly a century. The company's R&D spending in 2024 was approximately $30.5 billion on a GAAP basis (which includes significant charges related to business development transactions and acquired in-process research), or roughly $16.4 billion excluding those charges. Either way, the commitment is enormous.
More importantly, the kind of science Merck pursues has historically differed from the industry norm. Where many pharmaceutical companies have shifted toward "fast-follower" strategies — waiting for competitors to validate a mechanism of action and then developing a similar molecule — Merck has repeatedly pursued first-in-class approaches that carry higher scientific risk but offer greater commercial upside and competitive defensibility. Keytruda was not a me-too PD-1 inhibitor. Mectizan was not a minor iteration. Winrevair represents a genuinely novel mechanism for PAH.
This institutional bias toward scientific risk is self-reinforcing. It attracts researchers who want to work on hard problems. It creates a culture where breakthrough discoveries are celebrated in ways that cascade through hiring, retention, and internal mythology. It produces, occasionally, drugs so differentiated that they capture entire therapeutic categories. And it produces, inevitably, periods of pipeline drought when the hard problems prove harder than expected.
The company has been recognized repeatedly for its workplace culture — appearing on Fortune's "100 Best Companies to Work For" list multiple times — and the employee testimonials are striking in their specificity. Workers describe mentorship programs, flexibility for caregivers, and a genuine sense of purpose connected to patient outcomes. This is not incidental to the business model. In an industry where the median cost of bringing a single drug to market exceeds $1 billion and the failure rate exceeds 90%, the ability to attract and retain elite scientific talent is a structural competitive advantage.
— Kenneth C. Frazier, Forbes / JUST Capital recognition, 2020We believe that serving social good and securing long-term business success are deeply interdependent.
The NotPetya Scar and Other Unseen Risks
On June 27, 2017, a cyberattack attributed to Russian military intelligence struck Merck's global operations. The NotPetya malware — disguised as ransomware but actually designed for destruction — spread through a Ukrainian tax software update and cascaded across Merck's worldwide network. Manufacturing operations were disrupted for weeks. The company estimated the attack cost approximately $870 million in direct damages — a figure that, after a protracted legal battle with insurers, resulted in a landmark $1.4 billion settlement. The dispute centered on whether the cyberattack constituted an "act of war" excluded from standard commercial insurance policies.
NotPetya is worth dwelling on not because it was unique to Merck but because it exposed a vulnerability that the pharmaceutical industry shares with all complex global manufacturers: the fragility of interconnected digital systems. Merck has since invested heavily in cybersecurity — the company now describes its approach as a comprehensive overhaul — but the episode illustrates that existential risk in the pharmaceutical industry extends beyond patent cliffs and pipeline failures into domains that no amount of R&D spending can address.
The Clock and the Catalog
Robert Davis's strategic blueprint for Merck, as articulated through earnings calls and investor presentations in 2024 and 2025, can be summarized as a portfolio construction problem executed under extreme time pressure. The company must accomplish several things simultaneously:
Extend Keytruda's commercial life through subcutaneous reformulation, new indications, and combination therapies. Accelerate the launch and market penetration of Winrevair, targeting peak sales that some analysts estimate could exceed $5 billion annually. Advance the twenty potential blockbusters through clinical trials, regulatory approvals, and commercial launch. Execute business development — licensing deals, acquisitions, partnerships — to augment the pipeline where internal R&D cannot move fast enough. Manage the Gardasil franchise through its China disruption. Sustain the Animal Health business as a diversifying cash flow engine.
The 2025 financial outlook Merck provided in February projected worldwide sales between $64.1 billion and $65.6 billion, with non-GAAP EPS between $8.88 and $9.03. This implied modest top-line growth — essentially flat at the midpoint — as Keytruda's continued expansion was offset by Gardasil headwinds and the natural maturation of other products. The company also anticipated roughly $200 million in costs from tariff impacts, a reminder that pharmaceutical companies, for all their intellectual property moats, are not immune to the brute economics of global trade policy.
The market's verdict, reflected in the stock's decline from 2024 highs, was that Merck's execution plan was plausible but not yet proven. The pipeline assets are real but early. The Keytruda lifecycle extension is strategically sound but legally and commercially uncertain. The business development deals are promising but carry the execution risk inherent in any licensing arrangement. And the clock — 2028, when the core Keytruda patent expires — does not pause for clinical trials.
What George Merck Knew
George W. Merck — the grandson of the founder, the man who repurchased the seized company after World War I and led it through its transformation into a major American pharmaceutical enterprise — gave a speech in 1950 that is still quoted in Merck's corporate communications, still invoked by its leaders, still printed in its annual reports. The words are so embedded in the company's mythology that they function less as a statement of philosophy than as a kind of institutional catechism.
— George W. Merck, speech at the Medical College of Virginia, 1950We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear.
It is easy to be cynical about this kind of rhetoric — particularly when the company invoking it faces $29.5 billion in patent-protected revenue, prices its cancer immunotherapy at six figures per course of treatment, and operates in an industry where access remains catastrophically unequal across the globe. The cynicism is not entirely wrong. But it is not entirely right, either. The Mectizan program is real. The company's pricing access programs are, by industry standards, substantial. The culture that these words create — the scientists who take pay cuts to work at Merck rather than at hedge funds, the executives who frame decisions in terms of patient impact rather than quarterly earnings — is real and measurable in the quality of the pipeline, the caliber of the talent, and the longevity of the franchise.
The tension between the creed and the commercial reality is not a flaw in Merck's story. It is Merck's story. It is the tension that produces both the scientific ambition that leads to breakthrough drugs and the concentration risk that accompanies blockbuster dependence. A company that believed only in profits would diversify into contract manufacturing, financial services, anything to smooth the revenue curve. A company that believed only in the science would run itself into insolvency pursuing elegant molecules with no commercial application. Merck lives in the space between — sometimes uncomfortably, sometimes brilliantly.
In Rahway, New Jersey, in the laboratories where chemists once isolated lovastatin and immunologists first tested pembrolizumab in human subjects, a new generation of researchers is running trials on bispecific antibodies, oral GLP-1 agonists, personalized cancer vaccines, and RSV monoclonal antibodies. The clock reads 2028. The catalog reads twenty potential blockbusters. And on the wall somewhere, almost certainly, George Merck's words about medicine and profits — the ones that have never quite come true and never quite failed to appear.
Part IIThe Playbook
Merck's 130-year history offers a distinctive operating manual for building and sustaining a science-driven enterprise. The principles below are not platitudes about innovation — they are specific, evidence-based patterns that explain how the company created extraordinary value, why it repeatedly concentrated that value into dangerous dependencies, and what operators in any industry can learn from the tension between scientific ambition and commercial discipline.
Table of Contents
- 1.Let the bench scientist set the corporate agenda.
- 2.Win the race by months, not years.
- 3.Give away the thing that earns you the right to charge for everything else.
- 4.Expand the label until the molecule is a platform.
- 5.Acquire the mechanism, not the revenue.
- 6.Build the reformulation before the patent expires.
- 7.Maintain an uncorrelated revenue engine.
- 8.Hire for conscience, retain through mission.
- 9.Force-rank performance to kill the mediocrity equilibrium.
- 10.Treat the pipeline as a portfolio, not a lottery.
Principle 1
Let the bench scientist set the corporate agenda.
When Roy Vagelos took over Merck Research Laboratories in 1975, the company's R&D operation was competent but uninspired — driven by committee consensus rather than scientific conviction. Vagelos restructured it around the principle that the best researchers, not the most senior managers, should determine which programs received investment. He recruited heavily from academia, creating an environment where publishing in peer-reviewed journals was encouraged and where project selection was driven by the quality of the underlying biology, not market sizing exercises.
The results speak in product launches: lovastatin, enalapril, the recombinant hepatitis B vaccine, Mectizan. Every one of these drugs emerged from a research program that a purely commercial analysis might have deprioritized — lovastatin because the statin market didn't yet exist, Mectizan because the addressable population couldn't pay. Decades later, the same institutional bias toward science-led discovery produced Keytruda: Merck's researchers recognized the potential of PD-1 checkpoint inhibition before the clinical evidence was conclusive, and the company invested aggressively at a stage when the outcome was uncertain.
Benefit: Science-led discovery produces first-in-class products that capture entire therapeutic categories and create pricing power that fast-followers cannot replicate.
Tradeoff: Scientists are not portfolio managers. The bias toward breakthrough science can lead to underinvestment in incremental but commercially valuable improvements and creates periods of pipeline drought when the high-risk bets fail simultaneously.
Tactic for operators: If your company's competitive advantage depends on R&D, ensure that the people closest to the technical frontier have real authority over resource allocation — not just advisory roles. This means tolerating some amount of commercially irrational project selection in exchange for the optionality of breakthrough outcomes.
Principle 2
Win the race by months, not years.
Keytruda and Opdivo (Bristol-Myers Squibb's PD-1 inhibitor) target the same mechanism. Both are effective. Both would become multi-billion-dollar franchises. But Keytruda received FDA approval in September 2014; Opdivo followed in December 2014. Three months. That gap — along with Merck's aggressive clinical development strategy — allowed Keytruda to establish itself as the first-line standard of care in non-small cell lung cancer, the largest oncology indication by patient volume. By 2024, Keytruda's $29.5 billion in annual sales dwarfed Opdivo's revenue.
The lesson is not that being first always wins. It is that in winner-take-most therapeutic categories, the margin between dominance and runner-up status can be measured in weeks of regulatory timing, in a single pivotal trial reading out a quarter earlier, in a clinical development team that compressed their timeline by working weekends through the summer.
⏱
The Three-Month Advantage
PD-1 checkpoint inhibitor approvals and outcomes
| Drug | Company | First FDA Approval | 2024 Global Sales |
|---|---|---|---|
| Keytruda (pembrolizumab) | Merck | September 2014 | $29.5B |
| Opdivo (nivolumab) | Bristol-Myers Squibb | December 2014 | ~$9B |
Benefit: First-mover advantage in pharmaceutical markets compounds — early approvals drive clinical data generation, physician adoption, and guideline inclusion in a self-reinforcing cycle.
Tradeoff: Speed can compromise safety signal detection. The pressure to be first creates organizational stress and can lead to shortcuts that, as Vioxx demonstrated, carry catastrophic tail risk.
Tactic for operators: In markets with network effects or switching costs, small timing advantages can produce outsized outcomes. Invest in cycle-time compression as a strategic capability — not just in product quality, but in the speed of your development and go-to-market processes.
Principle 3
Give away the thing that earns you the right to charge for everything else.
The Mectizan Donation Program — manufacturing and distributing ivermectin free of charge to treat river blindness in perpetuity — is the most famous example, but it is not the only instance of Merck converting a philanthropic act into a strategic asset. The donation established Merck's reputation as the pharmaceutical company most committed to global health, which has had cascading effects on talent recruitment, government relationships, and institutional credibility in pricing negotiations.
This principle extends beyond charity. Merck has repeatedly made early investments in markets and populations that offered no immediate commercial return — building vaccine infrastructure in developing countries, conducting clinical trials in diseases of poverty, partnering with global health organizations — that later created relationships, capabilities, and reputational capital that proved commercially valuable.
Benefit: Authentic commitment to access and public health creates a moral brand equity that competitors cannot fabricate, supports talent acquisition, and builds institutional trust with regulators and governments.
Tradeoff: The boundary between strategic philanthropy and genuine altruism is inherently unstable. Cynics will always question motives. And the financial cost — Merck has donated over four billion treatments of Mectizan — is not trivial, even for a company of this size.
Tactic for operators: Identify one initiative where your company can make an outsized commitment that is genuinely aligned with your mission and that no competitor would credibly replicate. The investment should be large enough to be uncomfortable, visible enough to shape your reputation, and sustained enough to build compounding credibility.
Principle 4
Expand the label until the molecule is a platform.
Keytruda's journey from a single melanoma indication to more than 40 approved indications across dozens of tumor types is one of the most aggressive label-expansion campaigns in pharmaceutical history. Each new indication required its own clinical trial program, regulatory filing, commercial launch, and physician education effort. The cumulative effect was to transform a single molecule into a platform — a therapeutic infrastructure that touches nearly every major cancer type.
This strategy is expensive and risky. Each clinical trial represents a multi-million-dollar bet. Many fail. But the expected value of label expansion for a drug with Keytruda's established safety profile and commercial infrastructure is enormously positive: the fixed costs of manufacturing, distribution, and brand awareness are already sunk, so each additional indication contributes revenue at very high incremental margin.
Benefit: Label expansion converts a single drug into a diversified oncology franchise, reduces per-indication risk, and builds clinical data that reinforces physician confidence in the molecule.
Tradeoff: Expanding the label of a single drug deepens concentration risk. At 46% of total revenue, Keytruda's breadth of indications actually increases the severity of the patent cliff, because a broader base of revenue is exposed to biosimilar competition on the same timeline.
Tactic for operators: When you have a product with strong unit economics and broad applicability, invest aggressively in expanding its use cases before the competitive window closes. But track concentration metrics relentlessly — the same strategy that maximizes current revenue can create existential future risk.
Principle 5
Acquire the mechanism, not the revenue.
Merck's $11.5 billion acquisition of Acceleron Pharma in 2021 illustrates a pharmaceutical M&A philosophy that distinguishes the most successful acquirers from the rest. Acceleron had no significant commercial revenue at the time of the deal. What it had was sotatercept — a first-in-class activin signaling inhibitor for pulmonary arterial hypertension. Merck was buying a mechanism of action, a clinical program, and the scientific team that understood both. The bet paid off: Winrevair generated $419 million in its first partial year, and the launch trajectory suggests peak sales of potentially $5 billion or more.
Contrast this with the Schering-Plough acquisition in 2009 ($41 billion), which added revenue and scale but also complexity, integration challenges, and a portfolio of aging products. The lesson: in pharmaceuticals, value creation through M&A comes from acquiring novel science early, not from buying mature revenue at premium valuations.
Benefit: Mechanism-first acquisitions capture optionality at lower valuations than revenue-generating assets. They also bring scientific talent and institutional knowledge that can seed adjacent programs.
Tradeoff: Buying pre-revenue science means buying clinical risk. The majority of pipeline assets fail. A $11.5 billion bet on a single mechanism — no matter how promising — is a concentrated wager.
Tactic for operators: When acquiring companies or technologies, distinguish between buying proven revenue (which you will always overpay for) and buying scientific or technical capability at an earlier stage (where you can capture asymmetric upside). Develop the internal expertise to evaluate early-stage assets rigorously.
Principle 6
Build the reformulation before the patent expires.
The September 2025 FDA approval of subcutaneous Keytruda — years before the 2028 composition-of-matter patent expiration — is textbook lifecycle management, but the textbook rarely gets executed this well. Merck began the subcutaneous clinical development program early enough to have FDA approval, commercial infrastructure, and physician adoption in place before biosimilars could enter the market. The five-minute injection versus the thirty-minute infusion is not a marginal improvement — it is a step-function change in patient experience and healthcare system economics that creates genuine switching costs.
Benefit: Lifecycle management through reformulation extends the commercial window of a blockbuster drug, creates differentiation against biosimilars, and preserves pricing power.
Tradeoff: Reformulation strategies are well-known and sometimes perceived by payers and regulators as rent-seeking behavior. If the reformulation does not offer genuinely superior patient outcomes or economic value, it will face pushback from formulary committees and public opinion.
Tactic for operators: If your core product faces a competitive or contractual cliff, begin developing the next-generation version years before the cliff arrives. The reformulation must offer genuine value — not just patent extension — to survive scrutiny.
Merck's $5.9 billion Animal Health segment operates in a market with fundamentally different risk characteristics than human pharmaceuticals. Patent cliffs are less severe. Demand is driven by livestock economics and pet ownership trends rather than clinical guidelines and insurance coverage. Competitive dynamics favor incumbents with established distribution relationships. The business generates steady, predictable cash flow that can fund R&D investments with long and uncertain time horizons.
The recurring analyst calls for Merck to spin off Animal Health — arguing that the segment would command a higher valuation multiple as a standalone company — miss the strategic logic. In a company facing a $29.5 billion patent cliff, a $5.9 billion cash flow engine that is uncorrelated with oncology drug approval timelines is not a distraction. It is a shock absorber.
Benefit: Diversification into a business with different risk drivers provides financial stability, reduces the company's cost of capital, and funds long-duration R&D bets.
Tradeoff: Conglomerate structures are typically valued at a discount by equity markets. The operational and managerial complexity of running two distinct businesses — human pharma and animal health — consumes leadership bandwidth.
Tactic for operators: Before divesting a non-core business to "unlock value," calculate what that business contributes to your company's ability to absorb shocks and fund long-term investments. Financial optionality has value that market multiples do not capture.
Principle 8
Hire for conscience, retain through mission.
Merck has been named to Fortune's "100 Best Companies to Work For" list multiple times. Employee testimonials consistently cite the company's commitment to patient outcomes — not just compensation or perks — as a primary driver of engagement. When Kenneth Frazier resigned from the White House manufacturing council in 2017 over the Charlottesville crisis, internal employee surveys showed significant spikes in engagement and pride.
In an industry where the median tenure of a pharmaceutical researcher at a top-ten company is approximately five years, and where the competition for elite scientific talent includes not just other pharma companies but also biotech startups, tech companies, and academic institutions, the ability to retain researchers through mission alignment is a measurable competitive advantage.
Benefit: Mission-driven culture reduces attrition in expensive-to-replace scientific roles, attracts talent willing to accept lower compensation than alternative employers, and creates institutional continuity that supports long-duration R&D programs.
Tradeoff: Culture built on moral purpose can become brittle when the company faces ethical crises (Vioxx) or makes commercially necessary decisions (high drug pricing) that conflict with the stated mission. The gap between creed and practice is a permanent source of internal tension.
Tactic for operators: If your company's competitive advantage depends on retaining elite talent, invest in the intangible infrastructure of purpose — not just compensation, but authentic commitment to a mission that talented people want to dedicate their careers to. Then protect that mission with visible, sometimes costly, leadership decisions.
Principle 9
Force-rank performance to kill the mediocrity equilibrium.
In the mid-1980s, Merck confronted a problem common to large organizations: its performance evaluation system had devolved into uniformity, with outstanding performers receiving salary increases only marginally better than those given to average performers. Excellent work was not clearly identified; mediocrity was not penalized. In 1986, the company shifted to a forced-distribution system requiring managers to adhere to a prescribed distribution of performance ratings, with revised categories and a new discretionary award program.
The shift was controversial internally — forced-distribution systems always are — but it attacked the "Lake Wobegon problem" that plagues large organizations: when every employee is rated above average, performance evaluation ceases to convey information, and the organization loses its ability to allocate rewards in ways that reinforce excellence.
Benefit: Forced differentiation ensures that compensation tracks genuine performance, retains top performers who might otherwise leave for environments where their contributions are better recognized, and sends clear signals about organizational standards.
Tradeoff: Forced-distribution systems create anxiety, can damage collaboration (if employees view their peers as competitors for limited high ratings), and are particularly corrosive in research environments where output is stochastic and long-duration.
Tactic for operators: If your organization's performance distribution has compressed to the point where top performers and average performers receive similar rewards, the system is broken and you are slowly losing your best people. Introduce differentiation — not necessarily forced ranking, but some mechanism that visibly and meaningfully distinguishes outstanding contribution from adequate contribution.
Principle 10
Treat the pipeline as a portfolio, not a lottery.
Merck's announcement of 20 potential blockbusters with $50 billion in estimated cumulative revenue reflects a deliberate portfolio construction approach. Rather than betting the company on a single successor to Keytruda, the strategy diversifies across therapeutic areas (oncology, cardiovascular, metabolic, infectious disease), modalities (small molecules, biologics, vaccines, antibody-drug conjugates), and risk profiles (early-stage programs with high scientific risk alongside late-stage programs with more predictable trajectories).
This is the pharmaceutical equivalent of portfolio theory applied to R&D: no single asset needs to replace Keytruda's $29.5 billion. If ten drugs each achieve $2–5 billion in peak sales, the aggregate revenue can offset the cliff.
Benefit: Portfolio diversification across therapeutic areas and development stages reduces the variance of pipeline outcomes and increases the probability of maintaining revenue above a threshold.
Tradeoff: Diversification dilutes focus. Running 20 blockbuster programs simultaneously requires massive investment — Merck's R&D and business development spending exceeds $16 billion annually — and stretches organizational attention.
Tactic for operators: When facing the expiration of a dominant revenue source, resist the temptation to find a single replacement. Instead, construct a portfolio of bets with uncorrelated outcomes. The aggregate probability of maintaining revenue continuity is higher than the probability of any single bet succeeding.
Conclusion
The Compound of Science and Time
Merck's playbook is, at its core, a set of answers to a single question: How do you build a durable enterprise in an industry where every competitive advantage has an expiration date? The principles above — science-led discovery, speed to market, philanthropic credibility, label expansion, mechanism-based M&A, lifecycle management, diversification, mission-driven culture, performance differentiation, and portfolio construction — form an interlocking system. Each principle reinforces and constrains the others.
The system has produced, over 130 years, one of the most consequential medical companies in human history. It has also produced, with predictable regularity, moments of acute vulnerability when a single product dominates the portfolio and the patent clock begins to count down. The question facing Merck today is whether the system — refined through decades of crises, leadership transitions, and strategic pivots — can execute the most complex portfolio transition in pharmaceutical history. The playbook says yes. The clock says the answer is due by 2028.
Part IIIBusiness Breakdown
The Business at a Glance
Vital Signs
Merck & Co. — FY2024
$64.2BWorldwide sales (up 7% YoY; 10% ex-FX)
$29.5BKeytruda revenue (46% of total)
$7.65Non-GAAP EPS
$6.74GAAP EPS
~74,000Employees
~$200BApproximate market capitalization (mid-2025)
$5.9BAnimal Health revenue
Merck & Co. is the fourth-largest pharmaceutical company in the world by revenue, behind Johnson & Johnson, Roche, and Pfizer — though the ranking shifts year to year depending on how each company's portfolio cycles through patent expirations and new launches. The company operates from its headquarters in Rahway, New Jersey, with manufacturing facilities and R&D operations across the Americas, Europe, and Asia. Outside the United States and Canada, Merck operates under the name MSD (Merck Sharp & Dohme) — a legacy of the WWI-era corporate split from German parent Merck KGaA.
FY2024 was a year of contradictions. Revenue grew 7% (10% excluding foreign exchange) to $64.2 billion, driven by Keytruda's continued expansion and the successful launch of Winrevair. But Gardasil's China slowdown, elevated R&D spending tied to business development transactions, and the looming 2028 patent cliff weighed heavily on investor sentiment. Non-GAAP EPS of $7.65 included a net charge of $1.28 per share related to business development transactions, reflecting the company's aggressive pipeline-building activity.
The 2025 outlook of $64.1–65.6 billion in sales implies roughly flat top-line growth, as Keytruda's expansion is offset by Gardasil headwinds and the phasing of launch-stage products.
How Merck Makes Money
Merck's revenue is generated through two primary business segments — Pharmaceutical and Animal Health — with the pharmaceutical segment overwhelmingly dominant.
💊
Revenue Breakdown
FY2024 revenue by product and segment
| Product / Segment | FY2024 Revenue | % of Total | YoY Growth |
|---|---|---|---|
| Keytruda (oncology) | $29.5B | ~46% | +18% |
| Gardasil / Gardasil 9 (HPV vaccine) | $8.6B | ~13% | -3% |
| Januvia / Janumet (diabetes) | ~$2.7B (est.) | ~4% | Declining (generic competition) |
| Lagevrio (COVID-19 antiviral) | Declining | <1% | Significant decline |
| Winrevair (PAH) | $419M | <1% | New launch |
| Other Pharmaceutical | ~$17B (est.) | ~27% | Varies |
| Animal Health | $5.9B | ~9% | +4% |
Pharmaceutical segment (~91% of revenue): The engine of the enterprise. Revenue is generated through sales of prescription pharmaceuticals and vaccines to wholesalers, hospitals, government agencies, managed care organizations, and pharmacies worldwide. Pricing power is driven by patent exclusivity, clinical differentiation, and formulary position. Keytruda's pricing in the United States approaches approximately $190,000 per year for a full course of treatment at label doses, though the actual net price — after rebates, discounts, and 340B program pricing — is significantly lower.
Animal Health segment (~9% of revenue): Merck Animal Health sells products for livestock (poultry, cattle, swine) and companion animals (dogs, cats, horses). Revenue is driven by veterinary prescriptions, farmer purchasing cycles, and pet ownership trends. The segment benefits from less aggressive generic competition and more stable demand patterns than human pharmaceuticals.
Unit economics and margin profile: Merck's pharmaceutical gross margins are among the highest in the industry — characteristic of branded, patent-protected drugs. The company's overall GAAP operating margins are compressed by significant R&D spending and charges related to business development transactions. Non-GAAP operating margins, which exclude these charges, are more reflective of the underlying business economics.
Competitive Position and Moat
Merck competes across multiple therapeutic areas against the full spectrum of global pharmaceutical companies. Its competitive position varies significantly by franchise.
🏰
Competitive Landscape
Merck vs. key competitors by franchise
| Franchise | Key Competitors | Merck's Position | Moat Strength |
|---|---|---|---|
| Immuno-Oncology (PD-1) | BMS (Opdivo), Roche (Tecentriq), AstraZeneca (Imfinzi) | #1 globally by revenue | Strong (until 2028) |
| HPV Vaccines | GSK (Cervarix), Chinese domestic manufacturers | #1 globally | Eroding in China |
| Animal Health | Zoetis, Elanco, Boehringer Ingelheim | #2 globally | Stable |
| PAH (Winrevair) | J&J (Opsumit), United Therapeutics | Emerging leader (first-in-class mechanism) | Building |
| GLP-1 / Obesity | Eli Lilly (Zepbound), Novo Nordisk (Wegovy) | Early-stage entrant | Unproven |
Moat sources:
-
Patent exclusivity and regulatory data protection. Merck's core moat is intellectual property. Keytruda's composition-of-matter patent (expiring 2028) and the subcutaneous reformulation's additional protections provide legal barriers to competition. Gardasil's patents and manufacturing complexity create a different kind of moat — HPV vaccines are biologics that are inherently difficult to replicate.
-
Clinical data accumulation. Keytruda has been studied in more than 1,600 clinical trials across more than 30 tumor types. This vast dataset creates a self-reinforcing advantage: physicians trust the molecule because the evidence base is deeper than any competitor's, and the evidence base grows because physicians use the molecule.
-
Manufacturing scale and complexity. Biologics manufacturing — particularly for monoclonal antibodies like Keytruda — requires specialized facilities, sophisticated quality control, and years of process optimization. Biosimilar manufacturers will eventually replicate the molecule, but the manufacturing barrier delays and limits competition more than with small-molecule generics.
-
Global regulatory relationships. Merck's decades-long history of regulatory interaction with the FDA, EMA, and other agencies creates institutional knowledge and trust that accelerates approval timelines for new products.
-
Talent and culture. As discussed extensively in the Playbook, Merck's ability to recruit and retain elite scientific talent — driven by institutional reputation, mission alignment, and the Mectizan legacy — is a genuine competitive advantage in drug discovery.
Where the moat is weak or eroding:
The moat is strongest in the near term (2025–2028, while Keytruda patents hold) and weakest in the medium term (2029–2032, as biosimilar competition intensifies). The company's GLP-1 position is nascent and may never materialize into a competitive product. The Gardasil franchise faces structural erosion in China from domestic competitors. And the pipeline assets — while promising — are pre-revenue or early-revenue, meaning the competitive position they will ultimately create is uncertain.
The Flywheel
Merck's competitive flywheel operates on a multi-year cycle that is fundamentally different from the rapid-iteration flywheels of technology companies. In pharmaceuticals, the flywheel turns slowly — a single rotation can take a decade — but the compounding effects are enormous.
🔄
The Merck Flywheel
How scientific discovery compounds into commercial dominance
1. Science-led discovery → First-in-class molecules. Merck's institutional commitment to basic science and its ability to attract elite researchers produce novel drug candidates with differentiated mechanisms of action.
2. First-in-class molecules → Clinical evidence accumulation. Patent exclusivity and early approval allow Merck to run hundreds of clinical trials, building an evidence base that competitors cannot replicate because they entered the market later.
3. Clinical evidence accumulation → Physician adoption and guideline inclusion. As the evidence base grows, oncologists, cardiologists, and other specialists adopt the molecule as a standard of care. Treatment guidelines — issued by NCCN, ASCO, ESC, and other bodies — encode the molecule's position.
4. Guideline inclusion → Revenue and margin expansion. Once a drug is in treatment guidelines, utilization is driven by protocol rather than marketing. Revenue grows as new indications are added, and margins expand because the fixed costs of manufacturing and distribution are amortized over a larger revenue base.
5. Revenue and margin expansion → R&D reinvestment. The cash flows from blockbuster drugs fund the next generation of science-led discovery. Merck's R&D spending of $16+ billion annually (excluding business development charges) is funded primarily by Keytruda's cash generation.
6. R&D reinvestment → Next-generation molecules. The cycle restarts, with Winrevair, the bispecific antibody pipeline, the GLP-1 program, and the RSV monoclonal antibody all representing potential next-generation candidates.
The flywheel's vulnerability is the patent cliff: when step 1's output (the molecule) loses legal exclusivity, steps 2–5 collapse simultaneously. The entire flywheel depends on continuously feeding new first-in-class molecules into step 1 before the current generation loses protection.
Growth Drivers and Strategic Outlook
Merck's growth through 2030 depends on the successful execution of five specific vectors:
1. Keytruda lifecycle extension. The subcutaneous formulation, approved in September 2025, is the primary mechanism for preserving Keytruda revenue beyond the 2028 patent expiration. If Merck can convert a substantial portion of patients to the subcutaneous version — and if the reformulation's intellectual property protections withstand legal challenge — the revenue decline from biosimilar entry could be meaningfully less severe than current consensus estimates. The subcutaneous version also opens potential for self-administration in some settings, expanding access.
2. Winrevair (sotatercept) ramp. With $419 million in launch-year sales and a trajectory that some analysts project could reach $5 billion or more at peak, Winrevair is Merck's most important near-term growth driver outside of Keytruda. The drug's first-in-class mechanism for PAH, combined with expansion into broader cardiovascular indications, provides a long runway. TAM for PAH therapeutics alone is estimated at approximately $10 billion by 2030.
3. Pipeline maturation. The 20 potential blockbusters spanning oncology, cardiovascular, metabolic, infectious disease, and ophthalmology represent Merck's portfolio bet against Keytruda concentration risk. Key programs include bispecific antibodies (MK-2010, anti-PD-1/VEGF), oral GLP-1 agonists (MK-4082), RSV monoclonal antibodies (clesrovimab), and personalized cancer vaccines (V940, in partnership with Moderna). The $50 billion estimated cumulative revenue from these programs is aspirational but reflects real clinical assets at various stages of development.
4. GLP-1 market entry. The nearly $2 billion licensing deal with Hansoh for an oral GLP-1 receptor agonist positions Merck for potential participation in the obesity/diabetes market, which could exceed $100 billion annually by decade's end. Merck's entry is late and the competitive landscape is dominated by Eli Lilly and Novo Nordisk, but oral formulations could carve a differentiated niche if clinical results are strong.
5. Animal Health expansion. The segment's 8% constant-currency growth in 2024, including contributions from the recently acquired aquaculture portfolio, suggests continuing expansion. Global protein demand, pet humanization trends, and the need for food-safety solutions provide structural tailwinds.
Key Risks and Debates
1. The 2028 Keytruda patent cliff — the existential risk. This is not a generic risk factor. It is the single most important determinant of Merck's value over the next decade. Keytruda generated $29.5 billion in 2024. Even if the subcutaneous formulation preserves a significant portion of revenue, biosimilar competition could erode billions annually. The precise magnitude depends on biosimilar entry timing, payer behavior, physician switching patterns, and the legal durability of Merck's reformulation patents. Consensus estimates project Keytruda revenue declining 40–60% from peak by 2031 — a swing of $12–18 billion. No pharmaceutical company has ever navigated a cliff of this magnitude.
2. China Gardasil demand collapse. The pause in Gardasil shipments to China — which could extend through mid-2025 or beyond — reflects a structural shift, not a temporary inventory adjustment. Chinese domestic HPV vaccine manufacturers are entering the market with lower-cost alternatives. If China's share of Gardasil revenue declines permanently, the franchise could lose $2–3 billion in annual sales relative to prior expectations.
3. Pipeline execution risk. Of the 20 announced potential blockbusters, industry base rates suggest that roughly half will fail in clinical development or underperform commercially. The $50 billion revenue estimate is a best-case scenario. If key programs — particularly the bispecific antibodies and GLP-1 agonist — fail, Merck could face the 2028 cliff with insufficient replacement revenue.
4. Drug pricing and regulatory environment. The Inflation Reduction Act's Medicare drug price negotiation provisions have already begun to affect pharmaceutical industry dynamics. Keytruda is among the drugs subject to negotiation. Additionally, tariff-related costs — Merck estimated approximately $200 million in 2025 — and potential future trade policy changes could compress margins.
5. Competitive intensity in immuno-oncology. While Keytruda dominates the PD-1 space, next-generation immunotherapy approaches — bispecific antibodies, CAR-T cell therapies, tumor-infiltrating lymphocyte therapies, and novel checkpoint targets — could erode the PD-1 paradigm itself. Companies including Roche, AstraZeneca, and a wave of Chinese biotechs are investing heavily in approaches that could render PD-1 monotherapy a legacy standard of care.
Why Merck Matters
Merck's story is, in concentrated form, the story of the pharmaceutical industry's central tension: the extraordinary value that patent-protected innovation creates and the extraordinary vulnerability that patent expiration imposes. Every principle in Merck's playbook — the commitment to science-led discovery, the race for first-mover advantage, the aggressive label expansion, the lifecycle management through reformulation, the portfolio diversification of the pipeline — is an answer to this tension. And every answer creates its own secondary problems. Science-led discovery produces blockbusters but also concentration risk. Label expansion maximizes current revenue but deepens the cliff. Reformulation preserves the franchise but invites regulatory and public skepticism.
For operators and investors, the lesson is not specific to pharmaceuticals. Any business whose competitive advantage has an expiration date — whether it's a patent, a contractual exclusivity, a network effect that might be disrupted, or a technology moat that might be leapfrogged — faces the same fundamental challenge. The question is always the same: Can you build the next thing before the current thing expires? And can you do it without destroying the culture, the scientific capability, and the institutional integrity that produced the current thing in the first place?
Merck has answered this question successfully multiple times across 130 years — from statins to ACE inhibitors, from vaccines to checkpoint inhibitors, from Vagelos to Frazier to Davis. The answer has never been comfortable, never been certain, and never arrived ahead of schedule. The clock reads 2028. The flywheel is turning.
Why this matters next
business modelsNegative working capital / Cash-first
Get paid before you pay your suppliers. This model is all about optimizing cash flow, giving you capital to reinvest or pay down debt. It's financial engineerin
business modelsDirect sales / Network sales
Cut out the middleman. Sell straight to the consumer and pocket the difference. It's about controlling the customer experience and maximizing margins.
business modelsIngredient brand
Make your component so desirable that other products want to advertise your inclusion. It's about becoming the Intel Inside of your industry.
business modelsLicensing
Focus on creating intellectual property and let others handle the manufacturing. It's R&D as a business model.
business modelsFull-service / Integrated solution
Offer comprehensive coverage in your domain. It's about becoming indispensable to your customers.
mental modelsNetwork Effects
Merck Co applied the Network Effects mental model
Frequently asked questions
What is Merck & Co's business strategy?
Global pharmaceutical company. Maker of Keytruda (cancer), Gardasil (HPV vaccine), and many more.
What does Merck & Co do?
Global pharmaceutical company. Maker of Keytruda (cancer), Gardasil (HPV vaccine), and many more.
What business models does Merck & Co use?
Merck & Co is associated with: Negative working capital / Cash-first, Direct sales / Network sales, Ingredient brand, Licensing, Full-service / Integrated solution.
Where can I read more about Merck & Co?
This page provides a structured analysis of Merck & Co, including strategic moats and business model patterns where available.
Continue exploring
More like this, in your inbox
I send a newsletter every week — free, no spam, unsubscribe anytime.